心房颤动患者血浆纤溶抑制系统的变化

Plasma markers of fibrinolysis inhibitors in atrial fibrillation

目的:探讨心房颤动(房颤)患者血浆中纤溶抑制系统的变化。方法:将45例患者根据临床诊断分为3组:对照组(诊断为房性或室性期前收缩),特发性房颤组和房颤并发脑梗死组。3组患者年龄、TC和LDL差异无统计学意义(P>0.05),无其他临床并发症且未应用抗血栓治疗。取空腹外周血,用ELISA法检测血浆中凝血酶激活的纤溶酶抑制剂(TAFI)抗原、TAFI活性、纤溶酶-α2-抗纤溶酶复合物(PAP)和纤溶酶活化物抑制剂-1(PAI-1)。结果:3组患者血浆中TAFI、TAFI活性、PAP和PAI-1差异无统计学意义(P>0.05)。结论:房颤患者周围血中纤溶抑制系统指标变化不明显,心房局部纤溶抑制系统是否被激活及其在血栓形成中的意义需要进一步的研究。

Objective：To study effects of atrial fibrillation on plasma fibrinolysis inhibitors. Method： Forty-five patients were divided into three groups based on clinical diagnosis.. Group A, control, aged （71.1 ± 10. 1） years old,15 cases, male/female： 9/6. Group B, isolated atrial fibrillation, aged （70.1 ±7.9） years old, 15 cases, male/female： 9/6. Group C, atrial fibrillation with ischemic stroke, aged （73.8±9.7） years old, 15 cases, male/ female： 9/6. These three groups were similar in respect to age, total blood cholesterol and low-density-lipoprotein （P：〉0.05）. Fasting peripheral blood were obtained from all patients, and plasma thrombin-activable-fibrinolysisinhibitor （TAFI） antigen and activity, plasmin-α2 antiplasmin （PAP）, and plasmin-aetivator-inhibitor-1 （PAI-1） were measured. Result：There were no statistically significant difference in these markers of fibrinolysis inhibitors （P〉0.05）. Conclusion： Peripheral markers of fibrinolysis inhibitors did not increase in atrial fibrillation patients, and the relation between fibrinolysis inhibitors in atria and tbromboembolism need further investigation.